Voters should care about this bill because it directly addresses the high cost of prescription drugs, a major financial burden for many Americans, particularly those living on fixed incomes. If this bill passes, low-income Medicare beneficiaries would see a significant reduction, or even elimination, of copays for their medications, making essential drugs much more affordable and accessible. This could mean the difference between being able to afford life-saving medication or having to choose between medication and other necessities.
If the bill does not become law, these individuals will continue to pay their current copay amounts, which can pose a significant financial barrier to care and lead to worse health outcomes. The "Cutting Copays Act" aims to improve the quality of life for a vulnerable population by ensuring they can access the medications they need without undue financial strain.
KEY PROVISIONS
4AI-extracted
PROVISION 01
Sets maximum copays for low-income Medicare Part D beneficiaries at $1 for generic/preferred multiple-source drugs and $3 for other drugs for plan years before 2026.
This establishes the current limits for out-of-pocket drug costs before more significant changes take effect.
PROVISION 02
Eliminates copays (sets to $0) for generic drugs for low-income Medicare Part D beneficiaries starting in plan year 2026.
This provision significantly reduces or eliminates out-of-pocket costs for a very common and essential type of prescription drug.
PROVISION 03
For non-generic drugs, sets the copay for low-income individuals in plan year 2026 to the amount that was applied for such drugs in 2023.
This caps the copay for non-generic drugs at a previous, potentially lower, level, preventing future increases from previous trends.
PROVISION 04
Adjusts non-generic drug copays annually for inflation (based on the Consumer Price Index) in years following 2026.
This ensures that copayments keep pace with economic changes, preventing them from becoming disproportionately expensive over time.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Voters should care about this bill because it directly addresses the high cost of prescription drugs, a major financial burden for many Americans, particularly those living on fixed incomes. If this bill passes, low-income Medicare beneficiaries would see a significant reduction, or even elimination, of copays for their medications, making essential drugs much more affordable and accessible. This could mean the difference between being able to afford life-saving medication or having to choose between medication and other necessities.
If the bill does not become law, these individuals will continue to pay their current copay amounts, which can pose a significant financial barrier to care and lead to worse health outcomes. The "Cutting Copays Act" aims to improve the quality of life for a vulnerable population by ensuring they can access the medications they need without undue financial strain.
KEY PROVISIONS
AI-extracted
med
Sets maximum copays for low-income Medicare Part D beneficiaries at $1 for generic/preferred multiple-source drugs and $3 for other drugs for plan years before 2026.
This establishes the current limits for out-of-pocket drug costs before more significant changes take effect.
high
Eliminates copays (sets to $0) for generic drugs for low-income Medicare Part D beneficiaries starting in plan year 2026.
This provision significantly reduces or eliminates out-of-pocket costs for a very common and essential type of prescription drug.
med
For non-generic drugs, sets the copay for low-income individuals in plan year 2026 to the amount that was applied for such drugs in 2023.
This caps the copay for non-generic drugs at a previous, potentially lower, level, preventing future increases from previous trends.
med
Adjusts non-generic drug copays annually for inflation (based on the Consumer Price Index) in years following 2026.
This ensures that copayments keep pace with economic changes, preventing them from becoming disproportionately expensive over time.
Copay adjustments for other drugs are set to 2023 levels.
for a subsequent year
Annual inflation adjustments for non-generic drug copays begin.
GLOSSARY
AI-written
Medicare Part D
A government-run insurance program that helps cover the cost of prescription drugs for seniors and people with disabilities.
Cost-sharing reductions
Financial help given to eligible individuals to lower their out-of-pocket costs for healthcare, such as deductibles, copayments, and coinsurance.
Copayment (Copay)
A fixed amount you pay for a covered healthcare service or drug after you've paid your deductible.
Low-income individuals
People whose earnings are below a certain level, making them eligible for financial assistance programs.
Generic drug
A medication created to be the same as an existing approved brand-name drug in dosage, safety, strength, how it's taken, quality, and performance.
Preferred drug
A drug that is listed on a health plan's formulary (list of covered drugs) at a lower cost-sharing tier.
Plan year
The 12-month period that a health insurance plan covers.
ACTION TIMELINE
2 EVENTS
JUN 25, 25
Introduced in House
INTROREFERRAL
JUN 25, 25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
